Why I'm kicking myself I missed out on CSL shares

I'm still kicking myself on selling out of CSL Limited (ASX:CSL) shares. Here's why.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was March 2015, my hair was long, summer was on the run and I was about to buy my first bunch of ASX shares. After doing some reading and research, I had narrowed my selection to 5 or 6 ASX shares that I considered worthy of my first investment dollars.

Among this list was biotech company CSL Limited (ASX: CSL). I was enamoured with the company's products, its already impressive stock price growth and its dominance in the medical space and so went ahead and purchased about 35 shares at around $94 (read it and weep).

The CSL story

CSL is a true innovator and its blood plasma production remains one of the best and most fortified earning streams amongst medical stocks on the ASX. CSL's work with researching and manufacturing influenza vaccines through its Seqirus division places it at the forefront of the fight against the flu (this year's deadly flu season is a tragic reminder of the importance of this work).

Fast forward about three years and CSL had been my standout stock performer. Most of the other (in hindsight, pretty poor) stock picks had either gone backwards or stayed depressingly static – but CSL had charged ahead. I watched the stock price climb to $120, then to $140. At $150 I had thoughts about 'cashing out' and 'taking the profit', because that what the pros do and I thought I was a bit of a genius for latching onto such a winner. Finally, I relented and sold out at $161, taking an 80% profit and feeling pretty good. The price-to-earnings (P/E) ratio for CSL was very high (sitting around 40 if I remember) and I thought that I had ridden the wave to its height and it was about to crash, and I may as well take the cash off the table.

Alas, I then had to endure watching CSL smash through the $200 mark, then $220 and finally $230. Although CSL has since pulled back, it still has a P/E ratio in the high 30s and I learnt my lesson…

Foolish takeaway

If you get a fantastic company on the cheap, never, ever sell unless you have to! Good companies give back by compounding your money in a continuous cycle and the longer you hold the shares, the richer you will become. I wish I could go back and not hit the sell button – I have spent the last two years waiting for a 'buy-the-dip' opportunity to get back in (that still hasn't materialised). But such is life…

Sebastian Bowen (sadly) has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Share Market News

Brokers say these ASX 200 growth stocks could rise 50% to 70%

Analysts think these shares could be dirt cheap and destined to generate big returns.

Read more »

happy investor, share price rise, increase, up
Growth Shares

3 fantastic ASX 200 growth shares to buy in 2025

Analysts have good things to say about these buy-rated shares.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Growth Shares

The ASX 200 stock with 'a $200 billion gross profit opportunity'

Experts believe this stock has excellent potential.

Read more »

A young girl and boy drinking milk in a garden setting
Growth Shares

2 ASX growth shares set to skyrocket in the next 12 months

These stocks have a lot of potential according to experts.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 no-brainer ASX 200 shares to consider buying with just $1,000

Analysts rate these top stocks very highly. Let's find out why.

Read more »

A happy laughing surfer couple surfing together.
Growth Shares

If I were in my 20s, I'd buy these ASX shares for growth

I think these investments could be great picks for younger Aussies.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Growth Shares

Invest $5,000 into these ASX 200 shares in 2025

Analysts think these shares could be top options for an investment in 2025.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Growth Shares

3 explosive ASX growth shares to buy now

Analysts have good things to say about these growth shares.

Read more »